RTN4 and metabolic dysfunction-associated steatotic liver disease: Taken together, our findings in clinical specimens consolidate our findings that Nogo-B as a liver metabolic regulator reprograms the oxLDL lipophagy to enhance oncogenic YAP activity in NAFLD-associated HCCs (Fig. 7e).